Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Down 38.8% in January

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was the recipient of a significant decline in short interest during the month of January. As of January 15th, there was short interest totalling 93,300 shares, a decline of 38.8% from the December 31st total of 152,400 shares. Based on an average daily volume of 111,600 shares, the days-to-cover ratio is currently 0.8 days. Currently, 2.1% of the shares of the stock are short sold.

Brainstorm Cell Therapeutics Stock Performance

BCLI stock traded down $0.12 during trading on Thursday, hitting $1.91. The stock had a trading volume of 58,172 shares, compared to its average volume of 56,493. Brainstorm Cell Therapeutics has a 1-year low of $1.05 and a 1-year high of $11.89. The company’s 50 day moving average price is $1.95 and its two-hundred day moving average price is $2.96. The stock has a market cap of $10.89 million, a price-to-earnings ratio of -0.40 and a beta of 0.29.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Brainstorm Cell Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.